Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 247, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2022.115019
Keywords
Clk1; Kinase inhibitors; Benzothiophenes; Hydrazides; Anticancer agents; Chemical probes
Categories
Ask authors/readers for more resources
Clk1 kinase is a key modulator of pre-mRNA alternative splicing and could be a potential target for treating various tumors, Duchenne's muscular dystrophy, and viral infections. A new 5-methoxybenzothiophene scaffold was developed, enabling selective inhibition of Clk1 among isoenzymes. The derivatives 26a and 27a showed unprecedented selectivity and good growth inhibitory activity in cancer cells.
Clk1 kinase is a key modulator of the pre-mRNA alternative splicing machinery which has been proposed as a promising target for treatment of various tumour types, Duchenne's muscular dystrophy and viral infections such as HIV-1 and influenza. Most reported Clk1 inhibitors showed significant co-inhibition of Clk2 and Clk4 in particular, which limits their usefulness for deciphering the individual roles of the Clk1 isoform in physiology and disease. Herein, we present a new 5-methoxybenzothiophene scaffold, enabling for the first time selective inhibition of Clk1 even among the isoenzymes. The 3,5-difluorophenyl and 3,5-dichlorophenyl derivatives 26a and 27a (Clk1 IC50 = 1.4 and 1.7 nM, respectively) showed unprecedented selectivity factors of 15 and 8 over Clk4, and selectivity factors of 535 and 84 over Clk2. Furthermore, 26a and 27a exhibited good growth inhibitory activity in T24 cancer cells and long metabolic half-lives of almost 1 and 6.4 h, respectively. The overall favorable profile of our new Clk1 inhibitors suggests that they may be used in in vivo disease models or as probes to unravel the physiological or pathogenic roles of the Clk1 isoenzyme.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available